Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Melanoma 3Stomach Neoplasms 1Sarcoma, Synovial 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid 1Glioma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 18Nivolumab 7Cyclophosphamide 6fludarabine 5Docetaxel 4atezolizumab 3Specimen Handling 3Paclitaxel 3Ipilimumab 3Gemcitabine 3Drug Therapy 3Carboplatin 3Blood Specimen Collection 3ulixertinib 2poly ICLC 2fludarabine phosphate 2durvalumab 2Standard of Care 2Radiotherapy 2Radiation 2Observation 2Magnetic Resonance Spectroscopy 2Leucovorin 2Filgrastim 2Biopsy 2zimberelimab 1veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Immunotherapy, Adoptive × Dermatologic × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡